# Ambagon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ambagon-therapeutics

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.ambagontx.com
- Total disclosed funding: $45M
- Latest round: Series A (Jan 5, 2022)
- Investors on record: 8

## About

Ambagon Therapeutics Inc. innovates in drug development, focusing on therapeutics that target intrinsically disordered proteins, utilizing advanced molecular glue technology to address challenging diseases.Founded in 2020 and headquartered in San Carlos, US, Ambagon Therapeutics Inc. develops therapeutics aimed at traditionally undruggable proteins. The company has executed 3 deals, with the latest, a Series A funding round on January 5, 2022, raising USD 45 mn led by Nextech, and supported by investors such as AbbVie Biotech Ventures and RA Capital. The firm was founded by Christian Ottmann, while Scott Clarke serves as CEO.Ambagon Therapeutics specializes in developing innovative therapeutics that target intrinsically disordered proteins, deemed undruggable. Their proprietary platform employs 14-3-3 molecular glue technology, allowing modulation of protein-protein interactions and expanding the druggable proteome for various diseases including cancers and neurodegenerative disorders. The company serves North American and European markets, particularly partnering with biopharmaceutical firms in drug discovery.Ambagon Therapeutics generates revenue through strategic partnerships with biopharmaceutical companies that utilize its proprietary technology for drug development. The company typically enters collaborative agreements that include milestone payments and royalties, sharing research and development costs to create a viable financial structure. Success in advancing drug candidates through clinical trials and commercialization will drive revenue, although specific pricing structures or flagship products have not been disclosed.With the USD 45 mn raised in Series A funding on January 5, 2022, Ambagon Therapeutics aims to enhance its molecular glue platform and advance its drug pipeline. The funding will facilitate the development of new products targeting intrinsically disordered proteins and support entry into new markets, focusing on expanding partnerships with biopharmaceutical companies in both North America and Europe.

## Funding rounds

- Series A, Jan 5, 2022, $45M — Nextech, Inkef, AbbVie Ventures, RA Capital Management, Mission Biocapital, Droia Ventures, Surveyor Capital, MRL Ventures Fund

## Investors

- Nextech (https://capitalatlas.ai/funds/nextech) — Series A
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series A
- Surveyor Capital — Series A
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A